Research and Markets: PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/nsrz8b/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023" report to their offering.

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD.

The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Despite patent expiries for key products, Eli Lilly's Cymbalta in 2013, Otsuka Pharmaceutical/BMS's Abilify in 2016, and AstraZeneca's Seroquel XR in 2017, the MDD market value in Australia is not anticipated to decline, as generic products are priced similarly to branded products and any loss of market value due to potential price discounts is expected to be offset by the increasing prevalent cases of MDD, the launch of Brintellix and the potential introduction of late-stage pipeline products during the forecast period.

Scope

  • Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Australia including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Australia from 2013-2023.

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Unmet Needs and Opportunities

7 Pipeline Assessment

8 Market Outlook

9 Appendix

For more information visit http://www.researchandmarkets.com/research/nsrz8b/pharmapoint

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System